Tema Alternative Asset Managers ETF (PRVT)
Live price chart, market sentiment, and community perspectives for Tema Alternative Asset Managers ETF (CBOE: PRVT).
Live price chart, market sentiment, and community perspectives for Tema Alternative Asset Managers ETF (CBOE: PRVT).
From a market sentiment perspective, launching late 2025 under AAUM and subsequently rebranding to PRVT in mid-2026 hasn't saved this fund from severe growing pains. We're looking at a steep 21% year-to-date drawdown right out of the gate. Retail investors are steering clear because the narrative of long-term private market growth is completely overshadowed by near-term cyclical stagnation and a frozen transaction cycle.
On our desk, the liquidity profile for PRVT (formerly AAUM) is alarming. Microscopic daily trading volumes combined with an active 0.75% expense ratio create severe trading friction and structural scale risks. When you couple that with negative flows—such as YTD fund flows dropping over 80%—the execution risk makes position-building dangerous for anything beyond a micro-allocation.
As a risk manager reviewing the fund's operational setup, the recent name change from Tema Alternative Asset Managers ETF (AAUM) to Tema Listed Private Managers ETF (PRVT) per the June/July 2026 prospectus amendment highlights an attempt to repackage the product. However, severe fund outflows exceeding 80% year-to-date signal deep institutional and retail hesitation regarding current private credit stress and macroeconomic uncertainty.
When evaluating the quantitative framework of alternative asset manager ETFs against peers like Invesco's PSP, ProShares' PEX, WHITEWOLF's LBO, or State Street's KCE, PRVT suffers from a distinct lack of track record. If you are analyzing its baseline valuation, the forward P/E has compressed to roughly 15.1 following the 21% drawdown, offering baseline management fee support, but completely lacking near-term performance-fee catalysts.
From a portfolio construction angle, while private credit stress and alternative asset managers present an interesting macro thesis, PRVT's execution leaves much to be desired. Expected total returns over the next 6 to 12 months look constrained to the mid single-digits, driven entirely by fund yield rather than capital appreciation, making the 0.75% expense ratio difficult to justify for clients.
Explore plasma cleansing, somatic organ swaps, and BCI.